Business
Perimeter Medical Imaging AI to Present at the Life Sciences Virtual Investor Forum on June 12th
Perimeter Medical Imaging AI to Present at the Life Sciences Virtual Investor Forum on June 12th ...
About this update from Perimeter Medical Imaging Ai Inc
[{"type":"text","content":"\n\n\n\n Perimeter Medical Imaging AI to Present at the Life Sciences Virtual Investor Forum on June 12th\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n\n\n\n\n\n\n\n\n TORONTO\n \n and\n \n DALLAS\n \n\n ,\n \n\n June 10, 2025\n \n\n /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) (\"Perimeter\" or the \"Company\"), a commercial-stage medical technology company, is pleased to announce that its CEO,\n \n Adrian Mendes\n \n , will present an update on the Company's business at the Life Sciences Virtual Investor Forum on\n \n Thursday, June 12, 2025\n \n at\n \n 12:30 p.m. Eastern Time\n \n .\n \n\n A live stream of the presentation will be available\n \n here\n \n and on the\n \n Investors section\n \n of Perimeter's website, where it will also be archived for approximately 90 days.\n \n\n\n About Perimeter Medical Imaging AI, Inc.\n \n\n\n Based in\n \n Toronto, Canada\n \n and\n \n Dallas, Texas\n \n ,\n \n Perimeter Medical Imaging AI\n \n (TSX-V: PINK) (OTCQX: PYNKF) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that was recently evaluated in a pivotal clinical trial, with support from a grant of up to\n \n US$7.4 million\n \n awarded by the Cancer Prevention and Research Institute of\n \n Texas\n \n . The company's ticker symbol \"PINK\" is a reference to the pink ribbons used during Breast Cancer Awareness Month.\n \n\n\n Perimeter B-Series OCT is limited by U.S. law to investigational use and not available for sale in\n \n the United States\n \n . Perimeter S-Series OCT has 510(k) clearance under a general indication and has not been evaluated by the U.S....